A5327: Sofosbuvir + Ribavirin w/o Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)

Study Location:

BaltimoreWashington

Topic:

HIV

Clinicaltrials.gov Link:

https://clinicaltrials.gov/ct2/show/NCT02128217?term=a5327&rank=1

IRB#:

NA_00093365

Coordinator:

Anna Wimpelberg (Washington)

​Ilene Wiggins, RN (Baltimore)
 

Enrollment:

Closed

Trial Period:

Completed

A5327 SWIFT-C is a Phase I, open-label, two-cohort clinical trial, in which between 44 and 50 acutely HCV-infected HIV-1 positive subjects will be enrolled and administered oral sofosbuvir (SOF) in combination with weight-based ribavirin (RBV).

Men and women > 18 years, HIV+ and currently on stable antiretroviral (ARV) medications or on for at least 8 weeks and be newly infected (within the last 6 months) or recently re-infected with hepatitis C.

Anna Wimpelberg (Washington)
202-797-3589
awimpelberg@whitman-walker.org


​Ilene Wiggins, RN (Baltimore)
410-614-2766
iwiggin1@jhmi.edu

Categories

Location
Topic

Clinical Trials

P1108: A Phase I/II, Open-Label, Single Arm Study to...

This purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of bedaquiline (BDQ) in...

Read More

A5253: Sensitivity and Specificity of Mycobacterium...

An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...

Read More

NWCS 445: Novel Biomarkers to Shorten TB Treatment

Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...

Read More

A5342: Evaluating the Safety, Tolerability, and Effect of a...

The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...

Read More

A5329: Interferon –Free Therapy for Chronic Hepatitis C...

A5329 is a study for people who are infected with both HIV and the Hepatitis C virus (HCV) and have never taken Hepatitis C...

Read More